CoChat

Trial watch: STING agonists in cancer therapy

Open access
Le Naour, Julie, Zitvogel, Laurence, Galluzzi, Lorenzo, Vacchelli, Erika, Kroemer, Guido · 2020 · OncoImmunology

The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.

Abstract

Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA species in the cytosol. In particular, STING ensures the production of type I interferon (IFN) in response to invading DNA viruses, bacterial pathogens, as well as DNA leaking from mitochondria or the nucleus (e.g., in cells exposed to chemotherapy or radiotherapy). As a type I IFN is critical for the initiation of anticancer immune responses, the pharmaceutical industry has generated molecules that directly activate STING for use in oncological indications. Such STING agonists are being tested in clinical trials with the rationale of activating STING in tumor cells or tumor-infiltrating immune cells (including dendritic cells) to elicit immunostimulatory effects, alone or in combination with a range of established chemotherapeutic and immunotherapeutic regimens. In this Trial Watch, we discuss preclinical evidence and accumulating clinical experience shaping the design of Phase I and Phase II trials that evaluate the safety and preliminary efficacy of STING agonists in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1777624

Cites

192 of 192 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of STING signaling in cancer cells. Accumulation of double-stranded DNA (dsDNA) in the cytosol of cancer cells responding to some chemotherapeutics or radiation therapy boosts the enzymatic functions of cyclic GMP-AMP synthase (CGAS), resulting in the cyclic GMP-AMP (cGAMP)-dependent oligomerization and activation of stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) at the endoplasmic reticulum (ER). Activated STING promotes a TANK binding kinase 1 (TAK1)-dependent signal transduction cascade that initiates interferon regulatory factor 3 (IRF3)- and NF-κB-dependent transcription, potentially culminating with the secretion of numerous cytokines including type I interferon (IFN), interleukin 6 (IL-6) and tumor necrosis factor (TNF). CDN, cyclic dinucleotide; IκBα (official name: NFKBIA), NFKB inhibitor alpha; IKKα (official name: CHUK), component of inhibitor of nuclear factor-kappa B kinase complex; IKKβ (official name: IKBKB), inhibitor of nuclear factor-kappa B kinase subunit beta; PARP, poly(ADP-ribose) polymerase.
Figure 1 Overview of STING signaling in cancer cells. Accumulation of double-stranded DNA (dsDNA) in the cytosol of cancer cells responding to some chemotherapeutics or radiation therapy boosts the enzymatic functions of cyclic GMP-AMP synthase (CGAS), resulting in the cyclic GMP-AMP (cGAMP)-dependent oligomerization and activation of stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) at the endoplasmic reticulum (ER). Activated STING promotes a TANK binding kinase 1 (TAK1)-dependent signal transduction cascade that initiates interferon regulatory factor 3 (IRF3)- and NF-κB-dependent transcription, potentially culminating with the secretion of numerous cytokines including type I interferon (IFN), interleukin 6 (IL-6) and tumor necrosis factor (TNF). CDN, cyclic dinucleotide; IκBα (official name: NFKBIA), NFKB inhibitor alpha; IKKα (official name: CHUK), component of inhibitor of nuclear factor-kappa B kinase complex; IKKβ (official name: IKBKB), inhibitor of nuclear factor-kappa B kinase subunit beta; PARP, poly(ADP-ribose) polymerase.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 192 references

Research works printed but not linked: 3

  1. 135. Wang Z, Dove P, Rosa D, Bossen B, Helke S, Charbonneau M, Brinen L, Dodge K, Lin GH, Galligan C, et al. Preclinical charac­ terization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice. American Association of Cancer Research Annual Meeting 2019.
  2. 155. McKeage MJ, Jameson MB, Investigators ASSG. Comparative out­ comes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) retrospective analysis of pooled data. J Thorac Dis. 2010;2:199-204. doi:10.3978/j..2072-1439.2010.02.04.1. · doi:10.3978/j..2072-1439.2010.02.04.1
  3. 163. Endo A, Kim D, Huang K, Hao M, Mathieu S, Choi H, Majumder U, Zhu X, Shen Y, Sanders K, et al. Discovery of E7766: A representative of a novel class of macrocycle-bridged STING agonists (MBSAs) with superior potency and pan-genotypic activity. American Association for Cancer Research Annual Meeting 2019.

Cited by

See all 294

Metadata

Authors
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G.
Affiliations
  • Université de Paris, Sorbonne Université, INSERM, Centre de Recherche des Cordeliers
  • Inserm (FR)
  • Université Paris Cité (FR)
  • Université Paris-Sud (FR)
Corresponding author
  • Vacchelli, Erika
  • Kroemer, Guido
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1777624
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W4211021377
Cited by
289
References
189
Citations by year
2026: 27 · 2025: 43 · 2024: 37 · 2023: 63 · 2022: 56 · 2021: 61 · 2020: 2
FWCI
4.52
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • HAL (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Agence Nationale de la Recherche (ANR-18-IDEX-0001)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
STING agonist, STING, cancer immunotherapy, type I interferon, endoplasmic reticulum, cytosolic DNA sensing, pattern recognition receptors, tumor-infiltrating immune cells, dendritic cells, combination therapy with chemotherapy and radiotherapy, clinical trial design, drug safety and efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial watch: STING agonists in cancer therapy. https://app.cochat.ai/papers/10.1080/2162402x.2020.1777624
The paper
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020). Trial watch: STING agonists in cancer therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1777624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.